Tevogen Bio (NASDAQ:TVGN) had its price target lowered by analysts at D. Boral Capital from $10.00 to $5.00. They now have a "buy" rating on the stock.
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q [Yahoo! Finance]
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn